Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT05924269

Role of Neuronal Guidance Proteins as Diagnostic Markers for Acute Kidney Injury (AKI)

Status
Not Yet Recruiting
Phase
Study type
Observational
Enrollment
600 (estimated)
Sponsor
University Hospital Tuebingen · Academic / Other
Sex
All
Age
18 Years – 85 Years
Healthy volunteers
Not accepted

Summary

Acute kidney failure remains one of the most challenging entities to diagnose in clinical medicine, especially in the field of intensive care. The diagnosis of acute kidney injury is based solely on urine output and serum creatinine, both of which could also be influenced by other factors. A more sensitive and faster diagnostic option would not only be desirable but of utmost clinical importance. Therefore, the investigators aim to identify Neuronal Guidance Proteins (NGPs) as potential biomarkers for the identification and early detection of AKI with this investigation. This investigation aims to identify the possibility of diagnosing acute kidney injury, the subsequent validation of a potential biomarker will then have to take place in a multicenter study approach: Data in preclinical mouse models suggest that SEMA7A as one of the NGPs could be valuable as a biomarker, the study now aims to attempt a preliminary survey in humans and measure various NGPs.

Conditions

Timeline

Start date
2023-08-01
Primary completion
2026-07-01
Completion
2026-07-01
First posted
2023-06-29
Last updated
2023-07-05

Source: ClinicalTrials.gov record NCT05924269. Inclusion in this directory is not an endorsement.